These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9523738)

  • 1. Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
    MacLean FR; Skinner R; Hall AG; English M; Pearson AD
    Cancer Chemother Pharmacol; 1998; 41(5):413-6. PubMed ID: 9523738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesna excretion and ifosfamide nephrotoxicity in children.
    Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal dysfunctions secondary to ifosfamide treatment in children.
    Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
    J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
    Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
    Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic ifosfamide nephrotoxicity in children.
    Skinner R
    Med Pediatr Oncol; 2003 Sep; 41(3):190-7. PubMed ID: 12868118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide nephrotoxicity in children: histopathological features in two cases.
    Morland BJ; Mann JR; Milford DV; Raafat F; Stevens MC
    Med Pediatr Oncol; 1996 Jul; 27(1):57-61. PubMed ID: 8614393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide nephrotoxicity in pediatric cancer patients.
    Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
    Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of ifosfamide scheduling on acute nephrotoxicity in children.
    English MW; Skinner R; Pearson AD; Price L; Wyllie R; Craft AW
    Br J Cancer; 1997; 75(9):1356-9. PubMed ID: 9155058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child.
    Ashraf MS; Skinner R; English MW; Craft AW; Pearson AD
    Med Pediatr Oncol; 1997 Jan; 28(1):62-4. PubMed ID: 8950339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
    J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth impairment after ifosfamide-induced nephrotoxicity in children.
    Stöhr W; Patzer L; Paulides M; Kremers A; Beck JD; Langer T; Rossi R
    Pediatr Blood Cancer; 2007 May; 48(5):571-6. PubMed ID: 16755549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
    Canpolat C; Pearson P; Robertson R; Jaffe N
    Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide nephropathy in patients with sarcoma.
    Mashhadi MA; Sanadgol H; Keikhaei M
    Iran J Kidney Dis; 2011 Jul; 5(4):238-41. PubMed ID: 21725180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP; Epelman S; Bush DA
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers.
    Phillips RS; Tyerman K; Al-Kassim MI; Picton S
    Pediatr Hematol Oncol; 2008 Mar; 25(2):107-13. PubMed ID: 18363176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity after ifosfamide.
    Skinner R; Pearson AD; Price L; Coulthard MG; Craft AW
    Arch Dis Child; 1990 Jul; 65(7):732-8. PubMed ID: 2386379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.